ABEONA THERAPEUTICS INC

ABEO is the ticker symbol for Abeona Therapeutics, a clinical-stage biopharmaceutical company. Its stock represents equity ownership in the company and trades on the Nasdaq exchange. The share price reflects investor expectations about the company's pipeline and prospects. For the latest price and market data, see the live quote on this page.

ABEO operates in the biotechnology sector, specifically gene and cell therapy. The company focuses on developing treatments for rare genetic diseases. This industry is characterized by high research and development costs, regulatory oversight, and long timelines to commercialization. Success depends on clinical trial outcomes and regulatory approvals.

Recent performance for ABEO can be tracked using the price chart and performance metrics on this page. The stock may move on company announcements, clinical trial updates, or broader biotech market trends. For the most current performance figures, refer to the latest data displayed above, as prices change frequently during trading hours.

Determining whether ABEO is overvalued or undervalued requires analyzing its financials and pipeline. Biotech companies often have no revenue or earnings, so traditional metrics like P/E may not apply. Instead, investors may look at cash position, trial progress, and potential market size. For current valuation metrics, check the data on this page.

ABEO stock can be highly volatile due to its status as a clinical-stage biotech. News about trials, regulatory decisions, or financing can cause sharp price swings. Volatility may also be influenced by overall market conditions and small-cap stock dynamics. Investors should be aware of this risk when considering ABEO.

Key risks include clinical trial failures, regulatory delays, and the need for additional capital. As a biotech with no approved products, ABEO may have limited revenue and rely on financing. Competition, intellectual property challenges, and market volatility also pose risks. Investors should review SEC filings for detailed risk factors.